Emron Managed Care News
Obese patients taking the blood thinner warfarin
appear to have almost twice the risk of severe stomach bleeding compared to their normal-weight counterparts, a new study suggests.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 12 to 1 to recommend that the FDA approve Orkambi (lumacaftor/ivacaftor) for use in people with cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation in the CFTR gene.
Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. Baxter buys Sigma-Tau cancer drugs in $900m deal
Roche Lung-Cancer Drug Doubles Survival Rate in Trial
Roche Holding AG’s experimental immunotherapy for lung cancer doubled the likelihood of survival for some patients in a study, advancing development of a medicine that may help the Swiss drugmaker compete with Bristol-Myers Squibb Co. and Merck & Co.
A rrecent studyent study led by the Global eHealth Unit at the Imperial College London has found that the majority of insulin dosing apps are unreliable and put patients at risk of getting incorrect doses of insulin.
US regulators have questioned the clinical validity of Vertex’ cystic fibrosis combo Orkambi, which targets the most common form of the genetic condition, ahead of an advisory committee meeting this Tuesday (May 12).